Sun Pharmaceutical Industries has acquired the 12 per cent stake of Mark Mobius-headed Templeton Asset Management in its Israeli subsidiary, Taro Pharmaceuticals, for $82 million (Rs364 crore). Sun paid $16 per share, about 14 per cent premium to Taro's current market price of $13.75.
With this, Sun Pharma increased its Taro stake to 65.2 per cent from 53.2 per cent. Taro is a pink sheets-listed company on the New York Stock Exchange. The deal will help the Indian drug maker to get a crucial 77 per cent voting right on management decisions related to Taro. Templeton invested in Taro in 2005, and increased its stake in 2006, when Taro's shares were trading at $12. Templeton bought more shares in 2007 at between $6.50 and $7.20 per share.crackcrack
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: